Conditions: Hypercholesterolemia, Familial Heterozygous Familial Hypercholesterolemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial hypercholesterolemia.

Detailed description:

Arms:
arm 1: Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg arm 2: Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg

Interventions: intervention 1: MK-0524A intervention 2: MK-0524A
Intervention descriptions: intervention 1: 1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally intervention 2: 2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally

Protocol document: